Global Drug, Anti-infective Market Insights, Forecast to 2025

Report / Search Code: RnM2703783  Publish Date: 22 May, 2019

Price
1-user PDF : $ 3900.0  Site PDF : $ 5850.0  Enterprise PDF : $ 7800.0

Description:

Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright. Anti-infective is a general term that encompasses antibacterials, antibiotics, antifungals, antiprotozoans and antivirals.

The global Drug, Anti-infective market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drug, Anti-infective market based on company, product type, end user and key regions.

This report studies the global market size of Drug, Anti-infective in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Drug, Anti-infective in these regions.

This research report categorizes the global Drug, Anti-infective market by top players/brands, region, type and end user. This report also studies the global Drug, Anti-infective market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

GlaxoSmithKline
Merck
Pfizer
Novartis AG
Gilead Sciences
Abbott
Wyeth
Sanofi-Aventis
Bristol-Myers Squibb
Johnson
Roche Pharma AG
Nanosphere
NanoViricides
Novabay Pharmaceuticals
Obeotech
Optimer Pharmaceuticals
Basilea Pharmaceutica AG
Daichi Sankyo
MerLion Pharma
Theravance
Market size by Product
OTC
Rx Drugs
Market size by End User
Hospital
Drugs Store
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
The study objectives of this report are:

To study and analyze the global Drug, Anti-infective market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

To understand the structure of Drug, Anti-infective market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry specific challenges and risks).

Focuses on the key global Drug, Anti-infective companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

To project the value and sales volume of Drug, Anti-infective submarkets, with respect to key regions.

In this study, the years considered to estimate the market size of Drug, Anti-infective are as follows:

- **History Year**: 2014-2018
- **Base Year**: 2018
- **Estimated Year**: 2019
- **Forecast Year 2019 to 2025**

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Drug, Anti-infective market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

## Table of Contents

1 **Study Coverage**
   - 1.1 Drug, Anti-infective Product
   - 1.2 Market Segments
   - 1.3 Key Manufacturers Covered
   - 1.4 Market by Type
     - 1.4.1 Global Drug, Anti-infective Market Size Growth Rate by Product
     - 1.4.2 OTC
     - 1.4.3 Rx Drugs
   - 1.5 Market by End User
     - 1.5.1 Global Drug, Anti-infective Market Size Growth Rate by End User
     - 1.5.2 Hospital
     - 1.5.3 Drugs Store
     - 1.5.4 Other
   - 1.6 Study Objectives
   - 1.7 Years Considered

2 **Executive Summary**
   - 2.1 Global Drug, Anti-infective Market Size
     - 2.1.1 Global Drug, Anti-infective Revenue 2014-2025
     - 2.1.2 Global Drug, Anti-infective Sales 2014-2025
   - 2.2 Drug, Anti-infective Growth Rate by Regions
     - 2.2.1 Global Drug, Anti-infective Sales by Regions
     - 2.2.2 Global Drug, Anti-infective Revenue by Regions

3 **Breakdown Data by Manufacturers**
   - 3.1 Drug, Anti-infective Sales by Manufacturers
     - 3.1.1 Drug, Anti-infective Sales by Manufacturers
     - 3.1.2 Drug, Anti-infective Sales Market Share by Manufacturers
     - 3.1.3 Global Drug, Anti-infective Market Concentration Ratio (CR5 and HHI)
   - 3.2 Drug, Anti-infective Revenue by Manufacturers
     - 3.2.1 Drug, Anti-infective Revenue by Manufacturers (2014-2019)
     - 3.2.2 Drug, Anti-infective Revenue Share by Manufacturers (2014-2019)
   - 3.3 Drug, Anti-infective Price by Manufacturers
   - 3.4 Drug, Anti-infective Manufacturing Base Distribution, Product Types
     - 3.4.1 Drug, Anti-infective Manufacturers Manufacturing Base Distribution, Headquarters
     - 3.4.2 Manufacturers Drug, Anti-infective Product Type
     - 3.4.3 Date of International Manufacturers Enter into Drug, Anti-infective Market
   - 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 **Breakdown Data by Product**
   - 4.1 Global Drug, Anti-infective Sales by Product
   - 4.2 Global Drug, Anti-infective Revenue by Product
   - 4.3 Drug, Anti-infective Price by Product

5 **Breakdown Data by End User**
   - 5.1 Overview
   - 5.2 Global Drug, Anti-infective Breakdown Data by End User

6 **North America**
   - 6.1 North America Drug, Anti-infective by Countries
     - 6.1.1 North America Drug, Anti-infective Sales by Countries
     - 6.1.2 North America Drug, Anti-infective Revenue by Countries
     - 6.1.3 United States
     - 6.1.4 Canada
     - 6.1.5 Mexico
7 Europe
   - 7.1 Europe Drug, Anti-infective by Countries
     - 7.1.1 Europe Drug, Anti-infective Sales by Countries
     - 7.1.2 Europe Drug, Anti-infective Revenue by Countries
     - 7.1.3 Germany
     - 7.1.4 France
     - 7.1.5 UK
     - 7.1.6 Italy
     - 7.1.7 Russia
   - 7.2 Europe Drug, Anti-infective by Product
   - 7.3 Europe Drug, Anti-infective by End User

8 Asia Pacific
   - 8.1 Asia Pacific Drug, Anti-infective by Countries
     - 8.1.1 Asia Pacific Drug, Anti-infective Sales by Countries
     - 8.1.2 Asia Pacific Drug, Anti-infective Revenue by Countries
     - 8.1.3 China
     - 8.1.4 Japan
     - 8.1.5 Korea
     - 8.1.6 India
     - 8.1.7 Australia
     - 8.1.8 Indonesia
     - 8.1.9 Malaysia
     - 8.1.10 Philippines
     - 8.1.11 Thailand
     - 8.1.12 Vietnam
     - 8.1.13 Singapore
   - 8.2 Asia Pacific Drug, Anti-infective by Product
   - 8.3 Asia Pacific Drug, Anti-infective by End User

9 Central & South America
   - 9.1 Central & South America Drug, Anti-infective by Countries
     - 9.1.1 Central & South America Drug, Anti-infective Sales by Countries
     - 9.1.2 Central & South America Drug, Anti-infective Revenue by Countries
     - 9.1.3 Brazil
   - 9.2 Central & South America Drug, Anti-infective by Product
   - 9.3 Central & South America Drug, Anti-infective by End User

10 Middle East and Africa
   - 10.1 Middle East and Africa Drug, Anti-infective by Countries
     - 10.1.1 Middle East and Africa Drug, Anti-infective Sales by Countries
     - 10.1.2 Middle East and Africa Drug, Anti-infective Revenue by Countries
     - 10.1.3 GCC Countries
     - 10.1.4 Turkey
     - 10.1.5 Egypt
     - 10.1.6 South Africa
   - 10.2 Middle East and Africa Drug, Anti-infective by Product
   - 10.3 Middle East and Africa Drug, Anti-infective by End User

11 Company Profiles
   - 11.1 GlaxoSmithKline
     - 11.1.1 GlaxoSmithKline Company Details
     - 11.1.2 Company Business Overview
     - 11.1.4 GlaxoSmithKline Drug, Anti-infective Products Offered
     - 11.1.5 GlaxoSmithKline Recent Development
   - 11.2 Merck
     - 11.2.1 Merck Company Details
     - 11.2.2 Company Business Overview
     - 11.2.4 Merck Drug, Anti-infective Products Offered
     - 11.2.5 Merck Recent Development
   - 11.3 Pfizer
     - 11.3.1 Pfizer Company Details
     - 11.3.2 Company Business Overview
     - 11.3.3 Pfizer Drug, Anti-infective Sales, Revenue and Gross Margin (2014-2019)
     - 11.3.4 Pfizer Drug, Anti-infective Products Offered
     - 11.3.5 Pfizer Recent Development
   - 11.4 Novartis AG
     - 11.4.1 Novartis AG Company Details
     - 11.4.2 Company Business Overview
     - 11.4.3 Novartis AG Drug, Anti-infective Sales, Revenue and Gross Margin (2014-2019)
     - 11.4.4 Novartis AG Drug, Anti-infective Products Offered
     - 11.4.5 Novartis AG Recent Development
   - 11.5 Gilead Sciences
     - 11.5.1 Gilead Sciences Company Details
     - 11.5.2 Company Business Overview
     - 11.5.3 Gilead Sciences Drug, Anti-infective Sales, Revenue and Gross Margin (2014-2019)
     - 11.5.4 Gilead Sciences Drug, Anti-infective Products Offered
     - 11.5.5 Gilead Sciences Recent Development
   - 11.6 Abbott
     - 11.6.1 Abbott Company Details
     - 11.6.2 Company Business Overview
11.6.4 Abbott Drug, Anti-infective Products Offered
11.6.5 Abbott Recent Development

11.7 Wyeth
11.7.1 Wyeth Company Details
11.7.2 Company Business Overview
11.7.4 Wyeth Drug, Anti-infective Products Offered
11.7.5 Wyeth Recent Development

11.8 Sanofi-Aventis
11.8.1 Sanofi-Aventis Company Details
11.8.2 Company Business Overview
11.8.4 Sanofi-Aventis Drug, Anti-infective Products Offered
11.8.5 Sanofi-Aventis Recent Development

11.9 Bristol-Myers Squibb
11.9.1 Bristol-Myers Squibb Company Details
11.9.2 Company Business Overview
11.9.4 Bristol-Myers Squibb Drug, Anti-infective Products Offered
11.9.5 Bristol-Myers Squibb Recent Development

11.10 Johnson
11.10.1 Johnson Company Details
11.10.2 Company Business Overview
11.10.3 Johnson Drug, Anti-infective Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Johnson Drug, Anti-infective Products Offered
11.10.5 Johnson Recent Development

11.11 Roche Pharma AG
11.12 Nanosphere
11.13 NanoViricides
11.14 Novabay Pharmaceuticals
11.15 Obetech
11.16 Optimer Pharmaceuticals
11.17 Basilea Pharmaceutica AG
11.18 Daiichi Sankyo
11.19 MerLion Pharma
11.20 Theravance

12 Future Forecast
12.1 Drug, Anti-infective Market Forecast by Regions
12.1.1 Global Drug, Anti-infective Sales Forecast by Regions 2019-2025
12.1.2 Global Drug, Anti-infective Revenue Forecast by Regions 2019-2025
12.2 Drug, Anti-infective Market Forecast by Product
12.2.1 Global Drug, Anti-infective Sales Forecast by Product 2019-2025
12.2.2 Global Drug, Anti-infective Revenue Forecast by Product 2019-2025
12.3 Drug, Anti-infective Market Forecast by End User
12.4 North America Drug, Anti-infective Forecast
12.5 Europe Drug, Anti-infective Forecast
12.6 Asia Pacific Drug, Anti-infective Forecast
12.7 Central & South America Drug, Anti-infective Forecast
12.8 Middle East and Africa Drug, Anti-infective Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Drug, Anti-infective Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details